Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Authors:
- Steven G. PotkinSPSteven G. Potkin
- Anutosh R. SahaASAnutosh R. Saha
- Mary J. KujawaMKMary J. Kujawa
- William H. CarsonWCWilliam H. Carson
- Mirza AliMAMirza Ali
- Elyse StockESElyse Stock
- Joseph StringfellowJSJoseph Stringfellow
- Gary IngenitoGIGary Ingenito
- Stephen R. MarderSMStephen R. Marder
- 1 July 2003
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 60 (7) , 681-690
Abstract
Research from JAMA Psychiatry — Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective DisorderKeywords
This publication has 1 reference indexed in Scilit:
- Compliance with antipsychotic drug treatment: influence of side effectsActa Psychiatrica Scandinavica, 1994